{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T13:24:46Z","timestamp":1790774686445,"version":"4.1.0"},"reference-count":268,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100004312","name":"Eli Lilly and Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004312","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Advanced Drug Delivery Reviews"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.addr.2026.115893","type":"journal-article","created":{"date-parts":[[2026,5,9]],"date-time":"2026-05-09T15:12:13Z","timestamp":1778339533000},"page":"115893","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["High-dose biologics and bioconjugates delivery: Integrating molecular optimization with device design and routes of administration"],"prefix":"10.1016","volume":"235","author":[{"given":"Naresh K.","family":"Budhavaram","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin Harrison","family":"Duffy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abraham H.","family":"Abouzeid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reshma","family":"Bharadwaj","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nisha","family":"Shrestha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisa Schrader","family":"Echeverri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chris","family":"Mitchener","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. Anand","family":"Subramony","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.addr.2026.115893_bb0005","doi-asserted-by":"crossref","DOI":"10.1016\/j.addr.2024.115301","article-title":"Towards more tolerable subcutaneous administration: review of contributing factors for improving combination product design","volume":"209","author":"Mathias","year":"2024","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.addr.2026.115893_bb0010","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1007\/s12551-025-01346-2","article-title":"Developing high-concentration monoclonal antibody formulations for subcutaneous administration to improve patient treatment","volume":"17","author":"Mijangos","year":"2025","journal-title":"Biophys. Rev."},{"key":"10.1016\/j.addr.2026.115893_bb0015","doi-asserted-by":"crossref","DOI":"10.1080\/19420862.2023.2211185","article-title":"High concentration formulation developability approaches and considerations","volume":"15","author":"Zarzar","year":"2023","journal-title":"mAbs"},{"key":"10.1016\/j.addr.2026.115893_bb0020","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1186\/s12929-025-01190-2","article-title":"Technological advancements in antibody-based therapeutics for treatment of diseases","volume":"32","author":"Lu","year":"2025","journal-title":"J. Biomed. Sci."},{"key":"10.1016\/j.addr.2026.115893_bb0025","doi-asserted-by":"crossref","first-page":"159","DOI":"10.2147\/DDDT.S287323","article-title":"Subcutaneous delivery of high-dose\/volume biologics: current status and prospect for future advancements","volume":"15","author":"Badkar","year":"2021","journal-title":"Drug Des. Devel. Ther."},{"key":"10.1016\/j.addr.2026.115893_bb0030","doi-asserted-by":"crossref","first-page":"526","DOI":"10.5731\/pdajpst.2024.012980","article-title":"Evaluating unmet needs in large-volume subcutaneous drug delivery: US payer perspectives on a novel, large-volume on-body delivery system","volume":"78","author":"Desai","year":"2024","journal-title":"PDA J. Pharm. Sci. Technol."},{"key":"10.1016\/j.addr.2026.115893_bb0035","doi-asserted-by":"crossref","DOI":"10.1080\/19420862.2024.2402713","article-title":"Navigating large-volume subcutaneous injections of biopharmaceuticals: a systematic review of clinical pipelines and approved products","volume":"16","author":"Green","year":"2024","journal-title":"MAbs"},{"key":"10.1016\/j.addr.2026.115893_bb0040","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1080\/17425247.2023.2219891","article-title":"Autoinjectors for large-volume subcutaneous drug delivery: a review of current research and future directions","volume":"20","author":"Schneider","year":"2023","journal-title":"Expert Opin. Drug Deliv."},{"key":"10.1016\/j.addr.2026.115893_bb0045","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1111\/j.1600-065X.2008.00601.x","article-title":"Engineering therapeutic monoclonal antibodies","volume":"222","author":"Liu","year":"2008","journal-title":"Immunol. Rev."},{"key":"10.1016\/j.addr.2026.115893_bb0050","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1002\/cpt.3150","article-title":"Subcutaneous administration of monoclonal antibodies: pharmacology, delivery, immunogenicity, and learnings from applications to clinical development","volume":"115","author":"Davis","year":"2024","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.addr.2026.115893_bb0055","doi-asserted-by":"crossref","first-page":"2459","DOI":"10.2147\/PPA.S515565","article-title":"Patient experience and improvement opportunities in self-administered, large-volume subcutaneous infusions at home","volume":"19","author":"Franzese","year":"2025","journal-title":"Patient Prefer. Adherence"},{"key":"10.1016\/j.addr.2026.115893_bb0060","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1186\/s13223-024-00914-7","article-title":"Infusion parameters, safety, and practical guidance for the manual administration of subcutaneous immunoglobulin 20% (Ig20Gly)","volume":"20","author":"Grosse-Kreul","year":"2024","journal-title":"Allergy, Asthma Clin. Immunol."},{"key":"10.1016\/j.addr.2026.115893_bb0065","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1007\/s40259-018-0295-0","article-title":"Subcutaneous administration of biotherapeutics: an overview of current challenges and opportunities","volume":"32","author":"Bittner","year":"2018","journal-title":"BioDrugs"},{"key":"10.1016\/j.addr.2026.115893_bb0070","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1016\/j.xphs.2023.12.022","article-title":"A review of recent FDA-approved biologic-device combination products","volume":"113","author":"Guo","year":"2024","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.addr.2026.115893_bb0075","doi-asserted-by":"crossref","first-page":"2590","DOI":"10.1016\/j.xphs.2021.03.017","article-title":"A review of formulations of commercially available antibodies","volume":"110","author":"Strickley","year":"2021","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.addr.2026.115893_bb0080","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1093\/abt\/tbaf014","article-title":"Structure and function of therapeutic antibodies approved by the US FDA in 2024","volume":"8","author":"Strohl","year":"2025","journal-title":"Antibody Therapeut."},{"key":"10.1016\/j.addr.2026.115893_bb0085","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/j.jconrel.2018.08.001","article-title":"Subcutaneous delivery of monoclonal antibodies: how do we get there?","volume":"286","author":"Viola","year":"2018","journal-title":"J. Control. Release"},{"key":"10.1016\/j.addr.2026.115893_bb0180","unstructured":"Full Prescribing Information for REPATHA, US Food & Drug Administration, https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2025\/125522s045lbl.pdf, Accessed on 15 November 2025."},{"key":"10.1016\/j.addr.2026.115893_bb0185","unstructured":"Full Prescribing Information for RITUXAN HYCELA, US Food & Drug Administration, https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2021\/761064s013lbl.pdf, Accessed on 15 November 2025."},{"key":"10.1016\/j.addr.2026.115893_bb0190","unstructured":"Full Prescribing Information for RITUXAN (intravenous), US Food & Drug Administration, https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2012\/103705s5367s5388lbl.pdf, Accessed on 07 April 2026."},{"key":"10.1016\/j.addr.2026.115893_bb0195","unstructured":"Full Prescribing Information for HERCEPTIN HYLECTA, US Food & Drug Administration, https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2024\/761106s010lbl.pdf, Accessed on 15 November 2025."},{"key":"10.1016\/j.addr.2026.115893_bb0200","unstructured":"Full Prescribing Information for Herceptin (intravenous), US Food & Drug Aministration, https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2010\/103792s5250lbl.pdf, Accessed on 07 April 2026."},{"key":"10.1016\/j.addr.2026.115893_bb0205","unstructured":"Full Prescribing Information for PHESGO, US Food & Drug Administration, https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2024\/761170s007lbl.pdf, Accessed on 15 November 2025."},{"key":"10.1016\/j.addr.2026.115893_bb0210","unstructured":"Full Prescribing Information for PERJETA (intravenous), US Food & Drug Administration, https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2012\/125409lbl.pdf, Accessed on 07 April 2026."},{"key":"10.1016\/j.addr.2026.115893_bb0215","unstructured":"Full Prescribing Information for DARZALEX FASPRO, US Food & Drug Administration, https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2024\/761145s025lbl.pdf, Accessed on 15 November 2025."},{"key":"10.1016\/j.addr.2026.115893_bb0220","unstructured":"Full Prescribing Information for DARZALEX (intravenous), US Food & Drug Administration, https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2025\/761036s054lbl.pdf, Accessed on 07 April 2026."},{"key":"10.1016\/j.addr.2026.115893_bb0225","unstructured":"Full Prescribing Information for ULTOMIRIS, US Food & Drug Administration, https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2024\/761108s035lbl.pdf, Accessed on 15 November 2025."},{"key":"10.1016\/j.addr.2026.115893_bb0230","unstructured":"Full Prescribing Information for SKYRIZI, US Food & Drug Administration, https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2025\/761105s039,761262s011lbl.pdf, Accessed on 15 November 2025."},{"key":"10.1016\/j.addr.2026.115893_bb0235","unstructured":"Full Prescribing Informationfor RYSTIGGO, US Food & Drug Administration, https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2024\/761286s001lbl.pdf, Accessed on 15 November 2025."},{"key":"10.1016\/j.addr.2026.115893_bb0240","unstructured":"Full Prescribing Information for OPDIVO QVANTIG, US Food & Drug Administration, https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2025\/761381Orig1s000correctedlbl.pdf, Accessed on 15 November 2025."},{"key":"10.1016\/j.addr.2026.115893_bb0245","unstructured":"Full Prescribing Information for OPDIVO (Intravenous), US Food & Drug Administration, https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2025\/125554s132lbl.pdf, Accessed on 07 April 2026."},{"key":"10.1016\/j.addr.2026.115893_bb0250","unstructured":"Full Prescribing Information for TECENTRIQ HYBREZA, US Food & Drug Administration, https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2025\/761347Orig1s000Lbl.pdf, Accessed on 15 November 2025."},{"key":"10.1016\/j.addr.2026.115893_bb0255","unstructured":"Full Prescribing Information for TECENTRIQ (intravenous), US Food & Drug Administration, https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2020\/761034s025lbl.pdf, Accessed on 07 April 2026."},{"key":"10.1016\/j.addr.2026.115893_bb0260","unstructured":"Full Prescribing Information for KEYTRUDA QLEX, US Food & Drug Administration, https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2025\/761467s000lblOrig2.pdf, Accessed on 15 November 2025."},{"key":"10.1016\/j.addr.2026.115893_bb0265","unstructured":"Full Prescribing Information for KEYTRUDA (Intravenous), US Food & Drug Administration, https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2022\/125514s125lbl.pdf, Accessed on 07 April 2026."},{"key":"10.1016\/j.addr.2026.115893_bb0090","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1016\/j.annonc.2025.03.012","article-title":"Subcutaneous versus intravenous pembrolizumab, in combination with chemotherapy, for treatment of metastatic non-small-cell lung cancer: the phase III 3475A-D77 trial","volume":"36","author":"Felip","year":"2025","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.addr.2026.115893_bb0095","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.1182\/blood-2024-194612","volume":"144","author":"Bartlett","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.addr.2026.115893_bb0100","doi-asserted-by":"crossref","DOI":"10.1080\/19420862.2024.2443538","article-title":"Antibodies to watch in 2025","volume":"17","author":"Crescioli","year":"2025","journal-title":"MAbs"},{"key":"10.1016\/j.addr.2026.115893_bb0105","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1093\/abt\/tbab027","article-title":"US FDA-approved therapeutic antibodies with high-concentration formulation: summaries and perspectives","volume":"4","author":"Wang","year":"2021","journal-title":"Antibody Therapeut."},{"key":"10.1016\/j.addr.2026.115893_bb0110","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1007\/s11095-024-03683-5","article-title":"Clinical investigation of large volume subcutaneous delivery up to 25 mL for lean and non-lean subjects","volume":"41","author":"Dang","year":"2024","journal-title":"Pharm. Res."},{"key":"10.1016\/j.addr.2026.115893_bb0115","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1111\/cts.13109","article-title":"Clinical evaluation of large volume subcutaneous injection tissue effects, pain, and acceptability in healthy adults","volume":"15","author":"Woodley","year":"2022","journal-title":"Clin. Transl. Sci."},{"key":"10.1016\/j.addr.2026.115893_bb0120","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.addr.2020.05.009","article-title":"Predicting bioavailability of monoclonal antibodies after subcutaneous administration: open innovation challenge","volume":"167","author":"S\u00e1nchez-F\u00e9lix","year":"2020","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.addr.2026.115893_bb0125","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics10030083","article-title":"Overview of antibody drug delivery","volume":"10","author":"Awwad","year":"2018","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.addr.2026.115893_bb0130","doi-asserted-by":"crossref","first-page":"2986","DOI":"10.1007\/s12325-019-01101-6","article-title":"Subcutaneous injection of drugs: literature review of factors influencing pain sensation at the injection site","volume":"36","author":"Usach","year":"2019","journal-title":"Adv. Ther."},{"key":"10.1016\/j.addr.2026.115893_bb0135","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1080\/17425247.2022.2116425","article-title":"Enabling faster subcutaneous delivery of larger volume, high viscosity fluids","volume":"19","author":"Rini","year":"2022","journal-title":"Expert Opin. Drug Deliv."},{"key":"10.1016\/j.addr.2026.115893_bb0140","doi-asserted-by":"crossref","DOI":"10.1080\/19420862.2025.2577159","article-title":"Integrating computational simulation and high-throughput screening for the development of robust ultra-high concentration formulation of IgG1 antibody","volume":"17","author":"Lyu","year":"2025","journal-title":"mAbs"},{"key":"10.1016\/j.addr.2026.115893_bb0145","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1007\/s11095-024-03801-3","article-title":"Rapid development of high concentration protein formulation driven by high-throughput technologies","volume":"42","author":"Xin","year":"2025","journal-title":"Pharm. Res."},{"key":"10.1016\/j.addr.2026.115893_bb0150","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1186\/s12929-025-01141-x","article-title":"Accelerating antibody discovery and optimization with high-throughput experimentation and machine learning","volume":"32","author":"Matsunaga","year":"2025","journal-title":"J. Biomed. Sci."},{"key":"10.1016\/j.addr.2026.115893_bb0155","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1093\/abt\/tbae028","article-title":"Leveraging high-throughput analytics and automation to rapidly develop high-concentration mAb formulations: integrated excipient compatibility and viscosity screening","volume":"7","author":"Xin","year":"2024","journal-title":"Antibody Therapeut."},{"key":"10.1016\/j.addr.2026.115893_bb0160","first-page":"1","article-title":"Wearable devices for subcutaneous delivery of large-volume biologics: design, use, and regulatory perspective","author":"Sunstrom","year":"2025","journal-title":"Biomed. Mater. Devices"},{"key":"10.1016\/j.addr.2026.115893_bb0165","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1007\/s11095-010-0123-9","article-title":"Microneedle-based intradermal delivery enables rapid lymphatic uptake and distribution of protein drugs","volume":"28","author":"Harvey","year":"2011","journal-title":"Pharm. Res."},{"key":"10.1016\/j.addr.2026.115893_bb0170","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1007\/s11095-010-0177-8","article-title":"Rapid intradermal delivery of liquid formulations using a hollow microstructured array","volume":"28","author":"Burton","year":"2011","journal-title":"Pharm. Res."},{"key":"10.1016\/j.addr.2026.115893_bb0175","doi-asserted-by":"crossref","first-page":"3162","DOI":"10.1111\/bcp.14729","article-title":"Comprehensive evaluation of microneedle-based intradermal adalimumab delivery vs. subcutaneous administration: results of a randomized controlled clinical trial","volume":"87","author":"Jacobse","year":"2021","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.addr.2026.115893_bb0270","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1208\/s12248-012-9367-0","article-title":"Mechanistic determinants of biotherapeutics absorption following SC administration","volume":"14","author":"Richter","year":"2012","journal-title":"AAPS J."},{"key":"10.1016\/j.addr.2026.115893_bb0275","first-page":"1205121","article-title":"Factors affecting the absorption of subcutaneously administered insulin: effect on variability","volume":"1","author":"Gradel","year":"2018","journal-title":"J. Diabetes Res."},{"key":"10.1016\/j.addr.2026.115893_bb0280","doi-asserted-by":"crossref","DOI":"10.3390\/ijms20081811","article-title":"The dynamics of the skin\u2019s immune system","volume":"20","author":"Nguyen","year":"2019","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.addr.2026.115893_bb0285","doi-asserted-by":"crossref","DOI":"10.1186\/cc5069","article-title":"Bench-to-bedside review: the role of glycosaminoglycans in respiratory disease","volume":"10","author":"Souza-Fernandes","year":"2006","journal-title":"Crit. Care"},{"key":"10.1016\/j.addr.2026.115893_bb0290","doi-asserted-by":"crossref","DOI":"10.1002\/adma.202406604","article-title":"Landscape of subcutaneous administration strategies for monoclonal antibodies in oncology","volume":"36","author":"Jacquot","year":"2024","journal-title":"Adv. Mater."},{"key":"10.1016\/j.addr.2026.115893_bb0295","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.887402","article-title":"Targeting lymphatics for nanoparticle drug delivery","volume":"13","author":"McCright","year":"2022","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.addr.2026.115893_bb0300","doi-asserted-by":"crossref","DOI":"10.1016\/j.compbiomed.2024.109193","article-title":"The role of initial lymphatics in the absorption of monoclonal antibodies after subcutaneous injection","volume":"183","author":"Rahimi","year":"2024","journal-title":"Comput. Biol. Med."},{"key":"10.1016\/j.addr.2026.115893_bb0305","first-page":"257","article-title":"Monoclonal antitumor antibodies in the lymphatics","volume":"68","author":"Weinstein","year":"1984","journal-title":"Cancer Treat. Rep."},{"key":"10.1016\/j.addr.2026.115893_bb0310","doi-asserted-by":"crossref","first-page":"130s","DOI":"10.18433\/jpps30028","article-title":"Understanding the monoclonal antibody disposition after subcutaneous administration using a minimal physiologically based pharmacokinetic model","volume":"21","author":"Varkhede","year":"2018","journal-title":"J. Pharm. Pharm. Sci."},{"key":"10.1016\/j.addr.2026.115893_bb0315","doi-asserted-by":"crossref","DOI":"10.3390\/cancers12071868","article-title":"Development of antibody immuno-PET\/SPECT radiopharmaceuticals for imaging of oncological disorders-an update","volume":"12","author":"Dewulf","year":"2020","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.addr.2026.115893_bb0320","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/s13238-017-0408-4","article-title":"Pharmacokinetics of monoclonal antibodies and Fc-fusion proteins","volume":"9","author":"Liu","year":"2017","journal-title":"Protein Cell"},{"key":"10.1016\/j.addr.2026.115893_bb0325","doi-asserted-by":"crossref","first-page":"27186","DOI":"10.1038\/s41598-025-11168-7","article-title":"Advanced human FcRn knock-in mice for pharmacokinetic profiling of therapeutic antibodies","volume":"15","author":"Lee","year":"2025","journal-title":"Sci. Rep."},{"key":"10.1016\/j.addr.2026.115893_bb0330","doi-asserted-by":"crossref","first-page":"493","DOI":"10.2165\/11531280-000000000-00000","article-title":"Clinical pharmacokinetics of therapeutic monoclonal antibodies","volume":"49","author":"Keizer","year":"2010","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.addr.2026.115893_bb0345","article-title":"A physiologically based pharmacokinetic model relates the subcutaneous bioavailability of monoclonal antibodies to the saturation of FcRn-mediated recycling in injection-site-draining lymph nodes","volume":"13","author":"Stader","year":"2024","journal-title":"Antibodies (Basel)"},{"key":"10.1016\/j.addr.2026.115893_bb0350","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1007\/s11095-011-0578-3","article-title":"Subcutaneous absorption of monoclonal antibodies: role of dose, site of injection, and injection volume on rituximab pharmacokinetics in rats","volume":"29","author":"Kagan","year":"2012","journal-title":"Pharm. Res."},{"key":"10.1016\/j.addr.2026.115893_bb0355","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1007\/s40262-012-0027-4","article-title":"Pharmacokinetics, pharmacodynamics and physiologically-based pharmacokinetic modelling of monoclonal antibodies","volume":"52","author":"Dostalek","year":"2013","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.addr.2026.115893_bb0360","doi-asserted-by":"crossref","first-page":"1854","DOI":"10.1016\/j.xphs.2024.02.004","article-title":"Assessing physicochemical stability of monoclonal antibodies in a simulated subcutaneous environment","volume":"113","author":"Jogdeo","year":"2024","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.addr.2026.115893_bb0365","doi-asserted-by":"crossref","DOI":"10.3390\/antib8040056","article-title":"Understanding inter-individual variability in monoclonal antibody disposition","volume":"8","author":"Thomas","year":"2019","journal-title":"Antibodies"},{"key":"10.1016\/j.addr.2026.115893_bb0370","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1007\/BF01222209","article-title":"Absorption kinetics of subcutaneously injected insulin. evidence for degradation at the injection site","volume":"17","author":"Berger","year":"1979","journal-title":"Diabetologia"},{"key":"10.1016\/j.addr.2026.115893_bb0375","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/j.jconrel.2020.02.036","article-title":"Accelerating the development of novel technologies and tools for the subcutaneous delivery of biotherapeutics","volume":"321","author":"Collins","year":"2020","journal-title":"J. Control. Release"},{"key":"10.1016\/j.addr.2026.115893_bb0380","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2019.01540","article-title":"The neonatal fc receptor (FcRn): a misnomer?","volume":"10","author":"Pyzik","year":"2019","journal-title":"Front. Immunol."},{"key":"10.1016\/j.addr.2026.115893_bb0385","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1056\/NEJMoa063842","article-title":"Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412","volume":"355","author":"Suntharalingam","year":"2006","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.addr.2026.115893_bb0660","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1007\/s00125-020-05317-y","article-title":"A randomised, single-blind, placebo-controlled, dose-finding safety and tolerability study of the anti-CD3 monoclonal antibody otelixizumab in new-onset type 1 diabetes","volume":"64","author":"Keymeulen","year":"2021","journal-title":"Diabetologia"},{"key":"10.1016\/j.addr.2026.115893_bb0665","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1038\/nri3192","article-title":"The storm has cleared: lessons from the CD28 superagonist TGN1412 trial","volume":"12","author":"Hunig","year":"2012","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.addr.2026.115893_bb0670","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1056\/NEJMoa1304839","article-title":"Bapineuzumab, I clinical trial, two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer\u2019s disease","volume":"370","author":"Salloway","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.addr.2026.115893_bb0675","doi-asserted-by":"crossref","first-page":"8","DOI":"10.14283\/jpad.2018.1","article-title":"Delayed-start analyses in the Phase 3 Solanezumab EXPEDITION3 study in mild Alzheimer\u2019s disease","volume":"5","author":"Liu-Seifert","year":"2018","journal-title":"J. Prev Alzheimers Dis."},{"key":"10.1016\/j.addr.2026.115893_bb0680","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1186\/1756-8722-7-44","article-title":"A phase II study of dacetuzumab (SGN-40) in patients with relapsed diffuse large B-cell lymphoma (DLBCL) and correlative analyses of patient-specific factors","volume":"7","author":"de Vos","year":"2014","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.addr.2026.115893_bb0685","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.1200\/JCO.2015.63.2596","article-title":"A randomized, double-blind, placebo-controlled, Phase III study to assess efficacy and safety of weekly farletuzumab in combination with carboplatin and taxane in patients with ovarian cancer in first platinum-sensitive relapse","volume":"34","author":"Vergote","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.addr.2026.115893_bb0690","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1093\/annonc\/mdu517","article-title":"Randomized, phase III trial of figitumumab in combination with erlotinib versus erlotinib alone in patients with nonadenocarcinoma nonsmall-cell lung cancer","volume":"26","author":"Scagliotti","year":"2015","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.addr.2026.115893_bb0695","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0140-6736(13)61719-5","article-title":"Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial","volume":"383","author":"Fuchs","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.addr.2026.115893_bb0700","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1200\/JCO.2016.69.2160","article-title":"Results from the phase III randomized trial of onartuzumab plus erlotinib versus erlotinib in previously treated stage IIIB or IV non-small-cell lung cancer: METLung","volume":"35","author":"Spigel","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.addr.2026.115893_bb0390","doi-asserted-by":"crossref","first-page":"61","DOI":"10.4161\/mabs.3.1.13799","article-title":"Projecting human pharmacokinetics of therapeutic antibodies from nonclinical data: what have we learned?","volume":"3","author":"Deng","year":"2011","journal-title":"MAbs"},{"key":"10.1016\/j.addr.2026.115893_bb0395","first-page":"20","article-title":"Mechanistic considerations for the use of monoclonal antibodies for cancer therapy","volume":"11","author":"Glassman","year":"2014","journal-title":"Cancer Biol. Med."},{"key":"10.1016\/j.addr.2026.115893_bb0400","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.01951","article-title":"The molecular mechanisms that underlie the immune biology of anti-drug antibody formation following treatment with monoclonal antibodies","volume":"11","author":"Vaisman-Mentesh","year":"2020","journal-title":"Front. Immunol."},{"key":"10.1016\/j.addr.2026.115893_bb0405","doi-asserted-by":"crossref","first-page":"256","DOI":"10.4161\/mabs.2.3.11641","article-title":"The immunogenicity of humanized and fully human antibodies: residual immunogenicity resides in the CDR regions","volume":"2","author":"Harding","year":"2010","journal-title":"MAbs"},{"key":"10.1016\/j.addr.2026.115893_bb0410","doi-asserted-by":"crossref","first-page":"314","DOI":"10.4161\/self.1.4.13904","article-title":"Immunogenicity of protein therapeutics: the key causes, consequences and challenges","volume":"1","author":"Baker","year":"2010","journal-title":"Self Nonself"},{"key":"10.1016\/j.addr.2026.115893_bb0415","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1016\/j.xphs.2018.01.007","article-title":"Challenges and opportunities for the subcutaneous delivery of therapeutic proteins","volume":"107","author":"Turner","year":"2018","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.addr.2026.115893_bb0420","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.ymeth.2005.01.001","article-title":"Immunogenicity of engineered antibodies","volume":"36","author":"Hwang","year":"2005","journal-title":"Methods"},{"key":"10.1016\/j.addr.2026.115893_bb0425","doi-asserted-by":"crossref","DOI":"10.1186\/s12931-018-0859-z","article-title":"The use of intravenous versus subcutaneous monoclonal antibodies in the treatment of severe asthma: a review","volume":"19","author":"Matucci","year":"2018","journal-title":"Respir. Res."},{"key":"10.1016\/j.addr.2026.115893_bb0430","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1007\/s40744-020-00245-0","article-title":"Understanding and minimising injection-site pain following subcutaneous administration of biologics: a narrative review","volume":"7","author":"St Clair-Jones","year":"2020","journal-title":"Rheumatol. Ther."},{"key":"10.1016\/j.addr.2026.115893_bb0435","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/j.xphs.2015.11.002","article-title":"Immunogenicity of therapeutic protein aggregates","volume":"105","author":"Moussa","year":"2016","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.addr.2026.115893_bb0440","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1111\/j.1742-7843.2006.pto_271.x","article-title":"Pain perception after subcutaneous injections of media containing different buffers","volume":"98","author":"Laursen","year":"2006","journal-title":"Basic Clin. Pharmacol. Toxicol."},{"key":"10.1016\/j.addr.2026.115893_bb0445","doi-asserted-by":"crossref","first-page":"21","DOI":"10.3389\/fimmu.2016.00021","article-title":"Immunogenicity to biotherapeutics - the role of anti-drug immune complexes","volume":"7","author":"Krishna","year":"2016","journal-title":"Front. Immunol."},{"key":"10.1016\/j.addr.2026.115893_bb0450","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1177\/106002809603000703","article-title":"Pain assessment of subcutaneous injections","volume":"30","author":"Jorgensen","year":"1996","journal-title":"Ann. Pharmacother."},{"key":"10.1016\/j.addr.2026.115893_bb0455","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/j.ejpb.2017.06.029","article-title":"High-concentration protein formulations: how high is high?","volume":"119","author":"Garidel","year":"2017","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.addr.2026.115893_bb0460","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1002\/jps.20079","article-title":"Challenges in the development of high protein concentration formulations","volume":"93","author":"Shire","year":"2004","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.addr.2026.115893_bb0465","doi-asserted-by":"crossref","first-page":"4433","DOI":"10.1002\/jps.23324","article-title":"Investigating high-concentration monoclonal antibody powder suspension in nonaqueous suspension vehicles for subcutaneous injection","volume":"101","author":"Bowen","year":"2012","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.addr.2026.115893_bb0470","doi-asserted-by":"crossref","first-page":"1928","DOI":"10.1002\/jps.20347","article-title":"Reversible self-association increases the viscosity of a concentrated monoclonal antibody in aqueous solution","volume":"94","author":"Liu","year":"2005","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.addr.2026.115893_bb0475","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1016\/j.addr.2006.03.011","article-title":"Formulation and delivery issues for monoclonal antibody therapeutics","volume":"58","author":"Daugherty","year":"2006","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.addr.2026.115893_bb0480","doi-asserted-by":"crossref","first-page":"E501","DOI":"10.1208\/aapsj080359","article-title":"Effects of protein aggregates: an immunologic perspective","volume":"8","author":"Rosenberg","year":"2006","journal-title":"AAPS J."},{"key":"10.1016\/j.addr.2026.115893_bb0485","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/jps.20727","article-title":"Antibody structure, instability, and formulation","volume":"96","author":"Wang","year":"2007","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.addr.2026.115893_bb0490","doi-asserted-by":"crossref","first-page":"3261","DOI":"10.1021\/acs.molpharmaceut.5b00256","article-title":"Liquid-liquid phase separation in a dual variable domain immunoglobulin protein solution: effect of formulation factors and protein-protein interactions","volume":"12","author":"Raut","year":"2015","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.addr.2026.115893_bb0495","doi-asserted-by":"crossref","DOI":"10.1016\/j.xphs.2025.103877","article-title":"Current and emerging strategies for subcutaneous delivery of high-concentration and high-dose antibody therapeutics","volume":"114","author":"Ren","year":"2025","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.addr.2026.115893_bb0500","unstructured":"Full Prescribing Information for CIMZIA, US Food & Drug Administration, https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2019\/125160s289lbl.pdf, Accessed on 09 December 2025."},{"key":"10.1016\/j.addr.2026.115893_bb0505","unstructured":"Full Prescribing Information for BENLYSTA, US Food & Drug Administration, https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2018\/125370s062lbl.pdf, Accessed on 09 December 2025."},{"key":"10.1016\/j.addr.2026.115893_bb0510","unstructured":"Full Prescribing Information for HIZENTRA, US Food & Drug Administration, https:\/\/www.fda.gov\/media\/78466\/download?attachment, Accessed on 09 December 2025."},{"key":"10.1016\/j.addr.2026.115893_bb0515","doi-asserted-by":"crossref","first-page":"4149","DOI":"10.1002\/jps.22129","article-title":"Stabilization of lysozyme by benzyl alcohol: surface tension and thermodynamic parameters","volume":"99","author":"Goyal","year":"2010","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.addr.2026.115893_bb0520","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1002\/bit.22983","article-title":"Hydrophobic salts markedly diminish viscosity of concentrated protein solutions","volume":"108","author":"Du","year":"2011","journal-title":"Biotechnol. Bioeng."},{"key":"10.1016\/j.addr.2026.115893_bb0525","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1021\/acs.molpharmaceut.5b00817","article-title":"Therapeutic antibody engineering to improve viscosity and phase separation guided by crystal structure","volume":"13","author":"Chow","year":"2016","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.addr.2026.115893_bb0530","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1080\/19420862.2015.1128606","article-title":"Molecular basis of high viscosity in concentrated antibody solutions: strategies for high concentration drug product development","volume":"8","author":"Tomar","year":"2016","journal-title":"MAbs"},{"key":"10.1016\/j.addr.2026.115893_bb0535","doi-asserted-by":"crossref","first-page":"6592","DOI":"10.1021\/acs.jpcb.6b04907","article-title":"Coarse-grained antibody models for \u201cweak\u201d protein-protein interactions from low to high concentrations","volume":"120","author":"Calero-Rubio","year":"2016","journal-title":"J. Phys. Chem. B"},{"key":"10.1016\/j.addr.2026.115893_bb0540","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1021\/acs.molpharmaceut.0c01073","article-title":"Machine learning applied to determine the molecular descriptors responsible for the viscosity behavior of concentrated therapeutic antibodies","volume":"18","author":"Lai","year":"2021","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.addr.2026.115893_bb0545","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/j.jconrel.2006.05.027","article-title":"A recombinant human enzyme for enhanced interstitial transport of therapeutics","volume":"114","author":"Bookbinder","year":"2006","journal-title":"J. Control. Release"},{"key":"10.1016\/j.addr.2026.115893_bb0550","doi-asserted-by":"crossref","DOI":"10.1016\/j.jconrel.2025.02.069","article-title":"An industry perspective on hyaluronidase co-formulated biopharmaceutics","volume":"381","author":"Guo","year":"2025","journal-title":"J. Control. Release"},{"key":"10.1016\/j.addr.2026.115893_bb0555","doi-asserted-by":"crossref","first-page":"e272","DOI":"10.1016\/S2352-3026(17)30078-9","article-title":"Efficacy and safety of subcutaneous rituximab versus intravenous rituximab for first-line treatment of follicular lymphoma (SABRINA): a randomised, open-label, phase 3 trial","volume":"4","author":"Davies","year":"2017","journal-title":"Lancet Haematol."},{"key":"10.1016\/j.addr.2026.115893_bb0560","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1016\/S1470-2045(12)70329-7","article-title":"Subcutaneous versus intravenous administration of (neo)adjuvant trastuzumab in patients with HER2-positive, clinical stage I-III breast cancer (HannaH study): a phase 3, open-label, multicentre, randomised trial","volume":"13","author":"Ismael","year":"2012","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.addr.2026.115893_bb0565","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/S1470-2045(14)70005-1","article-title":"Pharmacokinetics and safety of subcutaneous rituximab in follicular lymphoma (SABRINA): stage 1 analysis of a randomised phase 3 study","volume":"15","author":"Davies","year":"2014","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.addr.2026.115893_bb0570","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1055\/s-0033-1363993","article-title":"Non-clinical pharmacokinetic\/pharmacodynamic and early clinical studies supporting development of a novel subcutaneous formulation for the monoclonal antibody rituximab","volume":"64","author":"Bittner","year":"2014","journal-title":"Drug Res. (Stuttg)"},{"key":"10.1016\/j.addr.2026.115893_bb0575","series-title":"Hyaluronidase","author":"M. Clinic","year":"2025"},{"key":"10.1016\/j.addr.2026.115893_bb0580","series-title":"HyQvia - Human Normal Immunoglobin","author":"E.M. Agency","year":"2021"},{"key":"10.1016\/j.addr.2026.115893_bb0585","unstructured":"Genentech, Herceptin, 20."},{"key":"10.1016\/j.addr.2026.115893_bb0590","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1186\/s43556-025-00299-y","article-title":"Hyaluronidase: structure, mechanism of action, diseases and therapeutic targets","volume":"6","author":"Lu","year":"2025","journal-title":"Mol. Biomed."},{"key":"10.1016\/j.addr.2026.115893_bb0595","doi-asserted-by":"crossref","first-page":"1867","DOI":"10.1007\/s11095-022-03294-y","article-title":"Mechanistic modeling of the effect of recombinant human Hyaluronidase (rHuPH20) on subcutaneous delivery of cetuximab in rats","volume":"39","author":"Gao","year":"2022","journal-title":"Pharm. Res."},{"key":"10.1016\/j.addr.2026.115893_bb0600","doi-asserted-by":"crossref","first-page":"283","DOI":"10.3109\/14764172.2015.1007069","article-title":"Allergic reaction to hyaluronidase use after hyaluronic acid filler injection","volume":"17","author":"Kim","year":"2015","journal-title":"J. Cosmet. Laser Ther."},{"key":"10.1016\/j.addr.2026.115893_bb0605","doi-asserted-by":"crossref","first-page":"23514","DOI":"10.1074\/jbc.M604292200","article-title":"Properties of human IgG1s engineered for enhanced binding to the neonatal Fc receptor (FcRn)","volume":"281","author":"Dall\u2019Acqua","year":"2006","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.addr.2026.115893_bb0340","doi-asserted-by":"crossref","DOI":"10.1186\/s13036-025-00506-y","article-title":"Engineering FcRn binding kinetics dramatically extends antibody serum half-life and enhances therapeutic potential","volume":"19","author":"Ko","year":"2025","journal-title":"J. Biol. Eng."},{"key":"10.1016\/j.addr.2026.115893_bb0610","doi-asserted-by":"crossref","first-page":"6147","DOI":"10.1128\/AAC.01285-13","article-title":"A novel investigational Fc-modified humanized monoclonal antibody, motavizumab-YTE, has an extended half-life in healthy adults","volume":"57","author":"Robbie","year":"2013","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.addr.2026.115893_bb0615","doi-asserted-by":"crossref","first-page":"4282","DOI":"10.1074\/jbc.M114.603712","article-title":"pH-dependent binding engineering reveals an FcRn affinity threshold that governs IgG recycling","volume":"290","author":"Borrok","year":"2015","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.addr.2026.115893_bb0620","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0212649","article-title":"Introduction of the YTE mutation into the non-immunogenic HIV bnAb PGT121 induces anti-drug antibodies in macaques","volume":"14","author":"Rosenberg","year":"2019","journal-title":"PLoS One"},{"key":"10.1016\/j.addr.2026.115893_bb0625","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1038\/nbt.1601","article-title":"Enhanced antibody half-life improves in vivo activity","volume":"28","author":"Zalevsky","year":"2010","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.addr.2026.115893_bb0630","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1038\/nature13612","article-title":"Enhanced neonatal fc receptor function improves protection against primate SHIV infection","volume":"514","author":"Ko","year":"2014","journal-title":"Nature"},{"key":"10.1016\/j.addr.2026.115893_bb0635","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1002493","article-title":"Safety and pharmacokinetics of the fc-modified HIV-1 human monoclonal antibody VRC01LS: a phase 1 open-label clinical trial in healthy adults","volume":"15","author":"Gaudinski","year":"2018","journal-title":"PLoS Med."},{"key":"10.1016\/j.addr.2026.115893_bb0640","doi-asserted-by":"crossref","first-page":"5031","DOI":"10.1038\/s41467-019-13108-2","article-title":"An engineered human fc domain that behaves like a pH-toggle switch for ultra-long circulation persistence","volume":"10","author":"Lee","year":"2019","journal-title":"Nat. Commun."},{"key":"10.1016\/j.addr.2026.115893_bb0645","doi-asserted-by":"crossref","first-page":"5526","DOI":"10.1016\/j.bbagen.2013.04.023","article-title":"Albumin as a versatile platform for drug half-life extension","volume":"1830","author":"Sleep","year":"2013","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.addr.2026.115893_bb0650","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1038\/nbt.1691","article-title":"Antibody recycling by engineered pH-dependent antigen binding improves the duration of antigen neutralization","volume":"28","author":"Igawa","year":"2010","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.addr.2026.115893_bb0655","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1038\/nrd2804","article-title":"Glycosylation as a strategy to improve antibody-based therapeutics","volume":"8","author":"Jefferis","year":"2009","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.addr.2026.115893_bb0745","unstructured":"Full Prescribing Information for AJOVY, US Food & Drug Administration, https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2025\/761089s031lbl.pdf, Accessed on 15 November 2025."},{"key":"10.1016\/j.addr.2026.115893_bb0750","unstructured":"Full Prescribing Information for COSENTYX, US Food & Drug Administration, https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2025\/125504Orig1s088,761349Orig1s008correctedlbl.pdf, Accessed on 15 November 2025."},{"key":"10.1016\/j.addr.2026.115893_bb0755","unstructured":"Full Prescribing Information for DUPIXENT, US Food & Drug Administration, Accessed on 15 November 2025."},{"key":"10.1016\/j.addr.2026.115893_bb0760","unstructured":"Full Prescribing Information for EBGLYSS, US Food & Drug Administration, https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2025\/761306s003lbl.pdf, Accessed on 15 November 2025."},{"key":"10.1016\/j.addr.2026.115893_bb0765","unstructured":"Full Prescribing Information for OMVOH, US Food & Drug Administration, https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2025\/761279s005lbl.pdf, Accessed on 15 November 2025."},{"key":"10.1016\/j.addr.2026.115893_bb0770","unstructured":"Full Prescribing Information for PRALUENT, US Food & Drug Administration, https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2025\/125559s047lblcorrection.pdf, Accessed on 15 November 2025."},{"key":"10.1016\/j.addr.2026.115893_bb0775","unstructured":"Full Prescribing Information for SILIQ, US Food & Drug Administration, https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2024\/761032s016lbl.pdf, Accessed on 15 November 2025."},{"key":"10.1016\/j.addr.2026.115893_bb0780","unstructured":"Full Prescribing Information for TEZSPIRE, US Food & Drug Administration, https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2025\/761224s006lbl.pdf, Accessed on 15 November 2025."},{"key":"10.1016\/j.addr.2026.115893_bb0785","unstructured":"Full Prescribing Information for TAKHZYRO, US Food & Drug Administration, https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2023\/761090s010lbl.pdf, Accessed on 15 November 2025."},{"key":"10.1016\/j.addr.2026.115893_bb0710","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1007\/s40259-023-00626-1","article-title":"Advancing subcutaneous dosing regimens for biotherapeutics: clinical strategies for expedited market access","volume":"38","author":"Bittner","year":"2024","journal-title":"BioDrugs"},{"key":"10.1016\/j.addr.2026.115893_bb0715","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1002\/cpdd.936","article-title":"Results of a dose-finding phase 1b study of subcutaneous Atezolizumab in patients with locally advanced or metastatic non-small cell lung cancer","volume":"10","author":"Felip","year":"2021","journal-title":"Clin. Pharmacol. Drug Dev."},{"key":"10.1016\/j.addr.2026.115893_bb0720","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1002\/jcph.1362","article-title":"Development of a subcutaneous fixed-dose combination of pertuzumab and trastuzumab: results from the phase Ib dose-finding study","volume":"59","author":"Kirschbrown","year":"2019","journal-title":"J. Clin. Pharmacol."},{"key":"10.1016\/j.addr.2026.115893_bb0725","doi-asserted-by":"crossref","DOI":"10.1016\/j.jconrel.2025.114156","article-title":"An industry perspective on clinical development and regulatory strategies for subcutaneously administered high-dose biologics","volume":"386","author":"Bruin","year":"2025","journal-title":"J. Control. Release"},{"key":"10.1016\/j.addr.2026.115893_bb0730","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1007\/s11095-020-02906-9","article-title":"Tissue resistance during large-volume injections in subcutaneous tissue of minipigs: Allmendinger and Fischer","volume":"37","author":"Allmendinger","year":"2020","journal-title":"Pharm. Res."},{"key":"10.1016\/j.addr.2026.115893_bb0735","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1016\/j.xphs.2016.04.009","article-title":"Understanding subcutaneous tissue pressure for engineering injection devices for large-volume protein delivery","volume":"105","author":"Doughty","year":"2016","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.addr.2026.115893_bb0705","doi-asserted-by":"crossref","DOI":"10.1016\/j.drudis.2025.104441","article-title":"On-body drug delivery systems: state-of-the-art technologies, clinical application, and future perspectives","volume":"30","author":"Dorati","year":"2025","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.addr.2026.115893_bb0740","doi-asserted-by":"crossref","unstructured":"N. Sunstrom, F.N. Sunstrum, Wearable devices for subcutaneous delivery of large-volume biologics: design, use, and regulatory perspective, (2025) 1\u201320.","DOI":"10.1007\/s44174-025-00479-y"},{"key":"10.1016\/j.addr.2026.115893_bb0790","doi-asserted-by":"crossref","DOI":"10.1080\/19420862.2023.2285277","article-title":"Monoclonal antibody and protein therapeutic formulations for subcutaneous delivery: high-concentration, low-volume vs. low-concentration, high-volume","volume":"15","author":"Desai","year":"2023","journal-title":"MAbs"},{"key":"10.1016\/j.addr.2026.115893_bb0795","series-title":"Unlocking Opportunities in On-Body Delivery Systems through a Platform Technology Approach","author":"Cuccato","year":"2024"},{"key":"10.1016\/j.addr.2026.115893_bb0840","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.1007\/s40265-015-0460-4","article-title":"Evolocumab: first global approval","volume":"75","author":"Markham","year":"2015","journal-title":"Drugs"},{"key":"10.1016\/j.addr.2026.115893_bb0845","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1007\/s40265-019-01068-2","article-title":"Ravulizumab: first global approval","volume":"79","author":"McKeage","year":"2019","journal-title":"Drugs"},{"key":"10.1016\/j.addr.2026.115893_bb0850","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1007\/s40265-019-01136-7","article-title":"Risankizumab: first global approval","volume":"79","author":"McKeage","year":"2019","journal-title":"Drugs"},{"key":"10.1016\/j.addr.2026.115893_bb0855","doi-asserted-by":"crossref","first-page":"2311","DOI":"10.1007\/s12325-023-02477-2","article-title":"Efficacy, safety, patient experience, and tolerability of risankizumab administered by on-body injector for moderate to severe Crohn\u2019s disease","volume":"40","author":"Loftus","year":"2023","journal-title":"Adv. Ther."},{"key":"10.1016\/j.addr.2026.115893_bb0860","doi-asserted-by":"crossref","first-page":"i1274","DOI":"10.1093\/ecco-jcc\/jjae190.0823","article-title":"P0649 acceptability and tolerance of Risankizumab treatment administered via on-body injector in patients with Crohn\u2019s disease: results of the Nationwide ACCEPT-OBI study","volume":"19","author":"Buisson","year":"2025","journal-title":"J. Crohn\u2019s Colitis"},{"key":"10.1016\/j.addr.2026.115893_bb0870","article-title":"Evaluating nurse preferences for a novel on-body delivery system vs. manual syringes for large-volume subcutaneous drug administration: a survey study","volume":"32","author":"Desai","year":"2025","journal-title":"Drug Deliv."},{"key":"10.1016\/j.addr.2026.115893_bb0875","unstructured":"Essential Drug Delivery Outputs for Devices Intended to Deliver Drugs and Biological Products - Guidance for Industry, US Food & Drug Administration, https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/essential-drug-delivery-outputs-devices-intended-deliver-drugs-and-biological-products, June 2024."},{"key":"10.1016\/j.addr.2026.115893_bb0865","doi-asserted-by":"crossref","first-page":"801","DOI":"10.2147\/CEOR.S317687","article-title":"Payer perspectives on intravenous versus subcutaneous administration of Drugs","volume":"13","author":"Epstein","year":"2021","journal-title":"Clinicoecon. Outcomes Res."},{"key":"10.1016\/j.addr.2026.115893_bb0880","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1080\/17425247.2023.2219891","article-title":"Autoinjectors for large-volume subcutaneous drug delivery: a review of current research and future directions","volume":"20","author":"Schneider","year":"2023","journal-title":"Expert Opin. Drug Deliv."},{"key":"10.1016\/j.addr.2026.115893_bb0895","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1080\/17425247.2020.1796630","article-title":"User experience for manual injection of 2 mL viscous solutions is enhanced by a new prefillable syringe with a staked 8 mm ultra-thin wall needle","volume":"17","author":"Pager","year":"2020","journal-title":"Expert Opin. Drug Deliv."},{"key":"10.1016\/j.addr.2026.115893_bb0900","article-title":"Subcutaneous drug delivery: adapting to high-viscosity, large-volume demands","volume":"166","author":"Fontanellaz","year":"2024","journal-title":"OnDrugDelivery. com"},{"key":"10.1016\/j.addr.2026.115893_bb0910","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1080\/17425247.2020.1704730","article-title":"Hold the device against the skin: the impact of injection duration on user\u2019s force for handheld autoinjectors","volume":"17","author":"Schneider","year":"2020","journal-title":"Expert Opin. Drug Deliv."},{"key":"10.1016\/j.addr.2026.115893_bb0915","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1007\/s12247-019-09414-3","article-title":"Challenges and considerations in development and manufacturing of high concentration biologics drug products","volume":"15","author":"Sahin","year":"2020","journal-title":"J. Pharm. Innov."},{"key":"10.1016\/j.addr.2026.115893_bb0920","first-page":"262","article-title":"US FDA-approved therapeutic antibodies with high-concentration formulation: summaries and perspectives","volume":"4","author":"Wang","year":"2021","journal-title":"Antib. Ther."},{"key":"10.1016\/j.addr.2026.115893_bb0930","doi-asserted-by":"crossref","DOI":"10.1177\/10781552251326574","article-title":"Evaluating pharmacist preferences: preparation of a novel on-body delivery system vs. high-resistance, manual syringes for large-volume subcutaneous drugs","author":"Desai","year":"2025","journal-title":"J. Oncol. Pharm. Pract."},{"key":"10.1016\/j.addr.2026.115893_bb0935","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.2217\/imt-2022-0097","article-title":"Systemic IgG exposure and safety in patients with primary immunodeficiency: a randomized crossover study comparing a novel investigational wearable infusor versus the Crono pump","volume":"14","author":"Wasserman","year":"2022","journal-title":"Immunotherapy"},{"key":"10.1016\/j.addr.2026.115893_bb0940","doi-asserted-by":"crossref","first-page":"2527","DOI":"10.1200\/JCO-25-00744","article-title":"Isatuximab subcutaneous by on-body injector versus Isatuximab intravenous plus pomalidomide and dexamethasone in relapsed\/refractory multiple myeloma: phase III IRAKLIA study","volume":"43","author":"Ailawadhi","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.addr.2026.115893_bb0945","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1080\/17425247.2022.2162037","article-title":"Understanding patient preferences for handheld autoinjectors versus wearable large-volume injectors","volume":"20","author":"Schneider","year":"2023","journal-title":"Expert Opin. Drug Deliv."},{"key":"10.1016\/j.addr.2026.115893_bb0950","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.addr.2019.10.004","article-title":"Intradermal and transdermal drug delivery using microneedles\u2013fabrication, performance evaluation and application to lymphatic delivery","volume":"153","author":"Sabri","year":"2020","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.addr.2026.115893_bb0955","doi-asserted-by":"crossref","DOI":"10.1155\/2019\/8303648","article-title":"Alternative methods of vaccine delivery: an overview of edible and intradermal vaccines","volume":"2019","author":"Criscuolo","year":"2019","journal-title":"J. Immunol. Res."},{"key":"10.1016\/j.addr.2026.115893_bb0960","doi-asserted-by":"crossref","DOI":"10.1016\/j.heliyon.2024.e40658","article-title":"A systematic review of microneedles technology in drug delivery through a bibliometric and patent overview","volume":"10","author":"Cammarano","year":"2024","journal-title":"Heliyon"},{"key":"10.1016\/j.addr.2026.115893_bb0965","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1080\/00914037.2018.1534113","article-title":"Dermal insulin delivery based on polymeric systems","volume":"68","author":"Darvishha","year":"2019","journal-title":"Int. J. Polym. Mater. Polym. Biomater."},{"key":"10.1016\/j.addr.2026.115893_bb0970","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1109\/JMEMS.2014.2307320","article-title":"Hypodermic-needle-like hollow polymer microneedle array: fabrication and characterization","volume":"23","author":"Wang","year":"2014","journal-title":"J. Microelectromech. Syst."},{"key":"10.1016\/j.addr.2026.115893_bb0975","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.3762\/bjnano.12.77","article-title":"An overview of microneedle applications, materials, and fabrication methods","volume":"12","author":"Rad","year":"2021","journal-title":"Beilstein J. Nanotechnol."},{"key":"10.1016\/j.addr.2026.115893_bb0980","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/j.ejps.2012.06.012","article-title":"Microneedle-mediated transdermal bacteriophage delivery","volume":"47","author":"Ryan","year":"2012","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.addr.2026.115893_bb0985","doi-asserted-by":"crossref","first-page":"2788","DOI":"10.1039\/D0LC00567C","article-title":"Hollow silicon microneedle fabrication using advanced plasma etch technologies for applications in transdermal drug delivery","volume":"20","author":"Bolton","year":"2020","journal-title":"Lab Chip"},{"key":"10.1016\/j.addr.2026.115893_bb0990","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1111\/cts.12567","article-title":"Tutorial on monoclonal antibody pharmacokinetics and its considerations in early development","volume":"11","author":"Ovacik","year":"2018","journal-title":"Clin. Transl. Sci."},{"key":"10.1016\/j.addr.2026.115893_bb0995","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1016\/j.addr.2012.04.005","article-title":"Microneedles for drug and vaccine delivery","volume":"64","author":"Kim","year":"2012","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.addr.2026.115893_bb1000","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1002\/jps.24277","article-title":"Anatomical, physiological, and experimental factors affecting the bioavailability of sc-administered large biotherapeutics","volume":"104","author":"Fathallah","year":"2015","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.addr.2026.115893_bb1005","doi-asserted-by":"crossref","first-page":"3162","DOI":"10.1111\/bcp.14729","article-title":"Comprehensive evaluation of microneedle-based intradermal adalimumab delivery vs. subcutaneous administration: results of a randomized controlled clinical trial","volume":"87","author":"Jacobse","year":"2021","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.addr.2026.115893_bb1010","doi-asserted-by":"crossref","unstructured":"A. Datta-Mannan, S. Estwick, C. Zhou, H. Choi, N.E. Douglass, D.R. Witcher, J. Lu, C. Beidler, R. Millican, Influence of physiochemical properties on the subcutaneous absorption and bioavailability of monoclonal antibodies, MAbs (Taylor & Francis), 2020, pp. 1770028.","DOI":"10.1080\/19420862.2020.1770028"},{"key":"10.1016\/j.addr.2026.115893_bb1015","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1038\/nrd4608","article-title":"From sewer to saviour\u2014targeting the lymphatic system to promote drug exposure and activity","volume":"14","author":"Trevaskis","year":"2015","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.addr.2026.115893_bb1020","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1006\/jsre.2000.6075","article-title":"Comparison of intradermal and subcutaneous injections in lymphatic mapping","volume":"96","author":"Kersey","year":"2001","journal-title":"J. Surg. Res."},{"key":"10.1016\/j.addr.2026.115893_bb1035","doi-asserted-by":"crossref","first-page":"6423","DOI":"10.1016\/j.vaccine.2007.05.046","article-title":"Echographic measurement of skin thickness in adults by high frequency ultrasound to assess the appropriate microneedle length for intradermal delivery of vaccines","volume":"25","author":"Laurent","year":"2007","journal-title":"Vaccine"},{"key":"10.1016\/j.addr.2026.115893_bb1040","doi-asserted-by":"crossref","first-page":"1810","DOI":"10.1016\/j.vaccine.2016.07.039","article-title":"High frequency ultrasound to assess skin thickness in healthy adults","volume":"35","author":"Van Mulder","year":"2017","journal-title":"Vaccine"},{"key":"10.1016\/j.addr.2026.115893_bb1045","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0086637","article-title":"Effects of age, gender, BMI, and anatomical site on skin thickness in children and adults with diabetes","volume":"9","author":"Derraik","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.addr.2026.115893_bb1030","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1111\/srt.12576","article-title":"Enhanced immunity in intradermal vaccination by novel hollow microneedles","volume":"24","author":"Ogai","year":"2018","journal-title":"Skin Res. Technol."},{"key":"10.1016\/j.addr.2026.115893_bb1050","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1056\/NEJMoa043540","article-title":"Dose sparing with intradermal injection of influenza vaccine","volume":"351","author":"Kenney","year":"2004","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.addr.2026.115893_bb1055","doi-asserted-by":"crossref","first-page":"5225","DOI":"10.1016\/j.vaccine.2015.06.075","article-title":"Comparison of lyophilized versus liquid modified vaccinia Ankara (MVA) formulations and subcutaneous versus intradermal routes of administration in healthy vaccinia-na\u00efve subjects","volume":"33","author":"Frey","year":"2015","journal-title":"Vaccine"},{"key":"10.1016\/j.addr.2026.115893_bb1025","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.4155\/tde.15.65","article-title":"Current opportunities and challenges in intradermal vaccination","volume":"6","author":"Chen","year":"2015","journal-title":"Ther. Deliv."},{"key":"10.1016\/j.addr.2026.115893_bb1060","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1023\/A:1015880819328","article-title":"Effect of molecular weight on the lymphatic absorption of water-soluble compounds following subcutaneous administration","volume":"7","author":"Supersaxo","year":"1990","journal-title":"Pharm. Res."},{"key":"10.1016\/j.addr.2026.115893_bb1065","doi-asserted-by":"crossref","first-page":"12434","DOI":"10.3389\/jpps.2024.12434","article-title":"Recent progress of polymeric microneedle-assisted long-acting transdermal drug delivery","volume":"27","author":"Meng","year":"2024","journal-title":"J. Pharm. Pharm. Sci."},{"key":"10.1016\/j.addr.2026.115893_bb1070","article-title":"Emergence of transdermal drug delivery technologies: a historical synopsis and systematic review on microneedles","volume":"1","author":"Ifekpolugo","year":"2024","journal-title":"Science"},{"key":"10.1016\/j.addr.2026.115893_bb1075","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1016\/j.ijpharm.2018.12.019","article-title":"Self-implanted tiny needles as alternative to traditional parenteral administrations for controlled transdermal drug delivery","volume":"556","author":"Chen","year":"2019","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.addr.2026.115893_bb1080","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1007\/s11095-013-1137-x","article-title":"Dissolvable microneedle arrays for intradermal delivery of biologics: fabrication and application","volume":"31","author":"Bediz","year":"2013","journal-title":"Pharm. Res."},{"key":"10.1016\/j.addr.2026.115893_bb1085","doi-asserted-by":"crossref","first-page":"3545","DOI":"10.1021\/acs.molpharmaceut.8b00544","article-title":"Microneedle-mediated transdermal delivery of bevacizumab","volume":"15","author":"Courtenay","year":"2018","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.addr.2026.115893_bb1090","unstructured":"(!!! INVALID CITATION !!! [213\u2013216])."},{"key":"10.1016\/j.addr.2026.115893_bb1095","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1016\/j.msec.2019.04.063","article-title":"3D printed microneedle patches using stereolithography (SLA) for intradermal insulin delivery","volume":"102","author":"Economidou","year":"2019","journal-title":"Mater. Sci. Eng. C"},{"key":"10.1016\/j.addr.2026.115893_bb1100","doi-asserted-by":"crossref","DOI":"10.1038\/s41378-019-0088-8","article-title":"Simple and customizable method for fabrication of high-aspect ratio microneedle molds using low-cost 3D printing","volume":"5","author":"Krieger","year":"2019","journal-title":"Microsyst. Nanoeng."},{"key":"10.1016\/j.addr.2026.115893_bb1105","doi-asserted-by":"crossref","DOI":"10.1063\/1.5127778","article-title":"A 3D-printed microfluidic-enabled hollow microneedle architecture for transdermal drug delivery","volume":"13","author":"Yeung","year":"2019","journal-title":"Biomicrofluidics"},{"key":"10.1016\/j.addr.2026.115893_bb1110","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1111\/j.1749-6632.2002.tb04880.x","article-title":"The role of interstitial stress in lymphatic function and lymphangiogenesis","volume":"979","author":"Swartz","year":"2002","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"10.1016\/j.addr.2026.115893_bb1120","series-title":"International Conference on Medical and Biological Engineering","first-page":"575","article-title":"Use of hollow microneedle drug delivery systems in treatment of diabetes mellitus","author":"Su\u0161i\u0107","year":"2019"},{"key":"10.1016\/j.addr.2026.115893_bb1125","article-title":"An idea of using microneedles for the targeted drug delivery to overcome the blood brain barrier for the treatment of brain diseases","author":"Agrawal","year":"2018","journal-title":"Aust. J. Pharm."},{"key":"10.1016\/j.addr.2026.115893_bb1130","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1109\/TBME.2007.906492","article-title":"Painless drug delivery through microneedle-based transdermal patches featuring active infusion","volume":"55","author":"Roxhed","year":"2008","journal-title":"IEEE Trans. Biomed. Eng."},{"key":"10.1016\/j.addr.2026.115893_bb1135","article-title":"Hollow microneedles as a flexible dosing control solution for transdermal drug delivery","volume":"32","author":"Kim","year":"2025","journal-title":"Mater. Today Bio"},{"key":"10.1016\/j.addr.2026.115893_bb1140","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1038\/s41378-025-01003-4","article-title":"High-precision transdermal drug delivery enabled by a dual-pump parallel valveless piezoelectric micropump integrated with hollow microneedles","volume":"11","author":"Zhang","year":"2025","journal-title":"Microsyst. Nanoeng."},{"key":"10.1016\/j.addr.2026.115893_bb1145","doi-asserted-by":"crossref","first-page":"71","DOI":"10.3390\/mi14010071","article-title":"A novel integrated transdermal drug delivery system with micropump and microneedle made from polymers","volume":"14","author":"Attiguppe","year":"2023","journal-title":"Micromachines"},{"key":"10.1016\/j.addr.2026.115893_bb1150","doi-asserted-by":"crossref","first-page":"792","DOI":"10.3390\/pharmaceutics15030792","article-title":"Microneedles in advanced microfluidic systems: a systematic review throughout lab and organ-on-a-chip applications","volume":"15","author":"Maia","year":"2023","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.addr.2026.115893_bb1155","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1038\/s41467-022-28579-z","article-title":"In-situ transfer vat photopolymerization for transparent microfluidic device fabrication","volume":"13","author":"Xu","year":"2022","journal-title":"Nat. Commun."},{"key":"10.1016\/j.addr.2026.115893_bb1160","doi-asserted-by":"crossref","DOI":"10.1088\/1361-6439\/aad301","article-title":"Development of SU-8 hollow microneedles on a silicon substrate with microfluidic interconnects for transdermal drug delivery","volume":"28","author":"Mishra","year":"2018","journal-title":"J. Micromech. Microeng."},{"key":"10.1016\/j.addr.2026.115893_bb1165","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1007\/s11095-005-8498-8","article-title":"Microinfusion using hollow microneedles","volume":"23","author":"Martanto","year":"2006","journal-title":"Pharm. Res."},{"key":"10.1016\/j.addr.2026.115893_bb1170","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/j.jconrel.2017.11.035","article-title":"Hollow microneedle-mediated micro-injections of a liposomal HPV E743\u201363 synthetic long peptide vaccine for efficient induction of cytotoxic and T-helper responses","volume":"269","author":"van der Maaden","year":"2018","journal-title":"J. Control. Release"},{"key":"10.1016\/j.addr.2026.115893_bb1175","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.adp3611","article-title":"A wearable osmotic microneedle patch provides high-capacity sustained drug delivery in animal models","volume":"16","author":"Zhao","year":"2024","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.addr.2026.115893_bb1180","doi-asserted-by":"crossref","first-page":"13256","DOI":"10.1021\/acsnano.3c00672","article-title":"Flexible electronic systems via electrohydrodynamic jet printing: a MnSe@ rGO cathode for aqueous zinc-ion batteries","volume":"17","author":"Wang","year":"2023","journal-title":"ACS Nano"},{"key":"10.1016\/j.addr.2026.115893_bb1185","author":"NanoPass Technologies Limited"},{"key":"10.1016\/j.addr.2026.115893_bb1190","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1186\/s13075-017-1323-z","article-title":"Lymphatic delivery of etanercept via nanotopography improves response to collagen-induced arthritis","volume":"19","author":"Aldrich","year":"2017","journal-title":"Arthritis Res. Ther."},{"key":"10.1016\/j.addr.2026.115893_bb1195","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1148\/radiol.2463070962","article-title":"Imaging of lymph flow in breast cancer patients after microdose administration of a near-infrared fluorophore: feasibility study","volume":"246","author":"Sevick-Muraca","year":"2008","journal-title":"Radiology"},{"key":"10.1016\/j.addr.2026.115893_bb1200","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.ejpb.2014.11.013","article-title":"Analysis of the absorption kinetics of macromolecules following intradermal and subcutaneous administration","volume":"89","author":"Milewski","year":"2015","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.addr.2026.115893_bb1205","doi-asserted-by":"crossref","first-page":"4465","DOI":"10.1021\/acs.molpharmaceut.4c00379","article-title":"Monoclonal antibody delivery using 3D printed biobased hollow \u03bcNe3dle arrays for the treatment of osteoporosis","volume":"21","author":"Uddin","year":"2024","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.addr.2026.115893_bb1210","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/j.jconrel.2018.12.026","article-title":"Intradermal delivery of vaccine nanoparticles using hollow microneedle array generates enhanced and balanced immune response","volume":"294","author":"Niu","year":"2019","journal-title":"J. Control. Release"},{"key":"10.1016\/j.addr.2026.115893_bb1215","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.jaad.2007.09.010","article-title":"Adalimumab therapy for moderate to severe psoriasis: a randomized, controlled phase III trial","volume":"58","author":"Menter","year":"2008","journal-title":"J. Am. Acad. Dermatol."},{"key":"10.1016\/j.addr.2026.115893_bb1220","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1109\/JMEMS.2003.820293","article-title":"Silicon micromachined hollow microneedles for transdermal liquid transport","volume":"12","author":"Gardeniers","year":"2003","journal-title":"J. Microelectromech. Syst."},{"key":"10.1016\/j.addr.2026.115893_bb1225","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/j.jconrel.2006.02.017","article-title":"Mechanism of fluid infusion during microneedle insertion and retraction","volume":"112","author":"Martanto","year":"2006","journal-title":"J. Control. Release"},{"key":"10.1016\/j.addr.2026.115893_bb1230","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1109\/JMEMS.2003.809959","article-title":"Side-opened out-of-plane microneedles for microfluidic transdermal liquid transfer","volume":"12","author":"Griss","year":"2003","journal-title":"J. Microelectromech. Syst."},{"key":"10.1016\/j.addr.2026.115893_bb1235","doi-asserted-by":"crossref","first-page":"13749","DOI":"10.1038\/s41598-018-32026-9","article-title":"Fluid absorption by skin tissue during intradermal injections through hollow microneedles","volume":"8","author":"Shrestha","year":"2018","journal-title":"Sci. Rep."},{"key":"10.1016\/j.addr.2026.115893_bb1240","first-page":"1","article-title":"Hollow microneedles: from materials to market\u2014a comprehensive review","author":"Anbazhagan","year":"2025","journal-title":"Microsyst. Technol."},{"key":"10.1016\/j.addr.2026.115893_bb1245","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/j.ijpharm.2015.06.025","article-title":"Controlled release of a model vaccine by nanoporous ceramic microneedle arrays","volume":"491","author":"Boks","year":"2015","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.addr.2026.115893_bb1250","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1007\/s10544-012-9717-9","article-title":"Hollow microneedles for intradermal injection fabricated by sacrificial micromolding and selective electrodeposition","volume":"15","author":"Norman","year":"2013","journal-title":"Biomed. Microdevices"},{"key":"10.1016\/j.addr.2026.115893_bb1255","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1021\/acs.molpharmaceut.7b00263","article-title":"Bioconjugate therapeutics: current progress and future perspective","volume":"14","author":"Li","year":"2017","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.addr.2026.115893_bb1260","doi-asserted-by":"crossref","first-page":"3526","DOI":"10.1007\/s11095-015-1657-7","article-title":"Current ADC linker chemistry","volume":"32","author":"Jain","year":"2015","journal-title":"Pharm. Res."},{"key":"10.1016\/j.addr.2026.115893_bb1265","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1186\/s12943-024-01963-7","article-title":"A review of the clinical efficacy of FDA-approved antibody\u2013drug conjugates in human cancers","volume":"23","author":"Liu","year":"2024","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.addr.2026.115893_bb1270","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1002\/cac2.12517","article-title":"Development of antibody-drug conjugates in cancer: overview and prospects","volume":"44","author":"Ruan","year":"2024","journal-title":"Cancer Commun. (Lond.)"},{"key":"10.1016\/j.addr.2026.115893_bb1275","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1056\/NEJMoa1814017","article-title":"Trastuzumab Emtansine for residual invasive HER2-positive breast cancer","volume":"380","author":"von Minckwitz","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.addr.2026.115893_bb1280","doi-asserted-by":"crossref","first-page":"2183","DOI":"10.1200\/JCO.2011.38.0410","article-title":"Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin\u2019s lymphoma","volume":"30","author":"Younes","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.addr.2026.115893_bb1285","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1056\/NEJMoa1914510","article-title":"Trastuzumab deruxtecan in previously treated HER2-positive breast cancer","volume":"382","author":"Modi","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.addr.2026.115893_bb1290","doi-asserted-by":"crossref","unstructured":"A. Bardia, S.A. Hurvitz, S.M. Tolaney, D. Loirat, K. Punie, M. Oliveira, A. Brufsky, S.D. Sardesai, K. Kalinsky, A.B. Zelnak, R. Weaver, T. Traina, F. Dalenc, P. Aftimos, F. Lynce, S. Diab, J. Cortes, J. O'Shaughnessy, V. Dieras, C. Ferrario, P. Schmid, L.A. Carey, L. Gianni, M.J. Piccart, S. Loibl, D.M. Goldenberg, Q. Hong, M.S. Olivo, L.M. Itri, H.S. Rugo, A.C.T. Investigators, Sacituzumab govitecan in metastatic triple-negative breast cancer, N. Engl. J. Med., 384 (2021) 1529\u20131541.","DOI":"10.1056\/NEJMoa2028485"},{"key":"10.1016\/j.addr.2026.115893_bb1295","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1056\/NEJMoa2035807","article-title":"Enfortumab vedotin in previously treated advanced urothelial carcinoma","volume":"384","author":"Powles","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.addr.2026.115893_bb1300","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1200\/JCO.19.00172","article-title":"Polatuzumab vedotin in relapsed or refractory diffuse large B-cell lymphoma","volume":"38","author":"Sehn","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.addr.2026.115893_bb1305","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/S1470-2045(19)30788-0","article-title":"Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study","volume":"21","author":"Lonial","year":"2020","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.addr.2026.115893_bb1310","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1016\/S1470-2045(21)00139-X","article-title":"Loncastuximab tesirine in relapsed or refractory diffuse large B-cell lymphoma (LOTIS-2): a multicentre, open-label, single-arm, phase 2 trial","volume":"22","author":"Caimi","year":"2021","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.addr.2026.115893_bb1315","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1016\/S1470-2045(21)00056-5","article-title":"Efficacy and safety of tisotumab vedotin in previously treated recurrent or metastatic cervical cancer (innovaTV 204\/GOG-3023\/ENGOT-cx6): a multicentre, open-label, single-arm, phase 2 study","volume":"22","author":"Coleman","year":"2021","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.addr.2026.115893_bb1320","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1200\/JCO.2016.69.9538","article-title":"Safety and activity of mirvetuximab soravtansine (IMGN853), a folate receptor alpha-targeting antibody-drug conjugate, in platinum-resistant ovarian, fallopian tube, or primary peritoneal cancer: a phase I expansion study","volume":"35","author":"Moore","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.addr.2026.115893_bb1325","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1038\/s41571-023-00850-2","article-title":"Exploring the next generation of antibody-drug conjugates","volume":"21","author":"Tsuchikama","year":"2024","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.addr.2026.115893_bb1330","doi-asserted-by":"crossref","first-page":"4361","DOI":"10.1039\/C8CS00676H","article-title":"Cleavable linkers in antibody-drug conjugates","volume":"48","author":"Bargh","year":"2019","journal-title":"Chem. Soc. Rev."},{"key":"10.1016\/j.addr.2026.115893_bb1335","doi-asserted-by":"crossref","first-page":"5901","DOI":"10.1093\/nar\/gkad415","article-title":"Targeted tissue delivery of RNA therapeutics using antibody-oligonucleotide conjugates (AOCs)","volume":"51","author":"Malecova","year":"2023","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.addr.2026.115893_bb1340","series-title":"Avidity Biosciences Announces FDA Removed Partial Clinical Hold on Delpacibart Etedesiran (Del-Desiran\/AOC 1001)","year":"2024"},{"key":"10.1016\/j.addr.2026.115893_bb1345","doi-asserted-by":"crossref","first-page":"14852","DOI":"10.1021\/acs.jmedchem.4c00802","article-title":"Structure-activity relationship of antibody-oligonucleotide conjugates: evaluating bioconjugation strategies for antibody-siRNA conjugates for drug development","volume":"67","author":"Cochran","year":"2024","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.addr.2026.115893_bb1350","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.154142","article-title":"Antibody-oligonucleotide conjugate achieves CNS delivery in animal models for spinal muscular atrophy","volume":"7","author":"Hammond","year":"2022","journal-title":"JCI Insight"},{"key":"10.1016\/j.addr.2026.115893_bb1355","series-title":"Avidity Biosciences Presents Positive Data from MARINA-OLE Demonstrating Reversal of Disease progression","year":"2024"},{"key":"10.1016\/j.addr.2026.115893_bb1360","series-title":"The First Global Phase 3 Trial of Delpacibart Etedesiran (del-desiran) for Treatment of DM1 and Provides Guidance on Regulatory Submission","author":"Avidity Biosciences Announces Completion of Enrollment for HARBOR\u2122","year":"2025"},{"key":"10.1016\/j.addr.2026.115893_bb1365","series-title":"Avidity Biosciences to Present Topline Data from Phase 1\/2 FORTITUDE\u2122 Trial of Del-Brax in People Living with Facioscapulohumeral Muscular Dystrophy at 32nd Annual","year":"2025"},{"key":"10.1016\/j.addr.2026.115893_bb1370","year":"2025"},{"key":"10.1016\/j.addr.2026.115893_bb1375","series-title":"Dyne Therapeutics Announces Positive Preliminary Data from ACHIEVE Phase 1\/2 Trial","year":"2024"},{"key":"10.1016\/j.addr.2026.115893_bb1380","series-title":"Dyne Therapeutics Announces New Long-Term Clinical Data from Phase 1\/2 DELIVER Trial of DYNE-251 in Duchenne Muscular Dystrophy Demonstrating Unprecedented and Sustained Functional Improvement Through 18 Months","year":"2025"},{"key":"10.1016\/j.addr.2026.115893_bb1385","series-title":"Arrowhead Pharmaceuticals Announces Development of ARO-DUX4 for FSHD","year":"2024"},{"key":"10.1016\/j.addr.2026.115893_bb1390","series-title":"Ultragenyx Announces Clinical Update for DTX401 Gene Therapy Program","year":"2024"},{"key":"10.1016\/j.addr.2026.115893_bb1395","doi-asserted-by":"crossref","DOI":"10.1002\/jimd.70014","article-title":"Safety and efficacy of DTX401, an AAV8-mediated liver-directed gene therapy, in adults with glycogen storage disease type I a (GSDIa)","volume":"48","author":"Weinstein","year":"2025","journal-title":"J. Inherit. Metab. Dis."},{"key":"10.1016\/j.addr.2026.115893_bb1400","article-title":"Engineered ultrasmall nanoparticle drug-immune conjugates with \u201chit and run\u201d tumor delivery to eradicate gastric cancer","volume":"6","author":"Zhang","year":"2023","journal-title":"Adv. Ther."},{"key":"10.1016\/j.addr.2026.115893_bb1405","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1038\/nrc.2016.108","article-title":"Cancer nanomedicine: progress, challenges and opportunities","volume":"17","author":"Shi","year":"2017","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.addr.2026.115893_bb1410","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/s41573-020-0090-8","article-title":"Engineering precision nanoparticles for drug delivery","volume":"20","author":"Mitchell","year":"2021","journal-title":"Nat. Rev. Drug Discov."}],"container-title":["Advanced Drug Delivery Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169409X26001274?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169409X26001274?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,7]],"date-time":"2026-06-07T08:56:40Z","timestamp":1780822600000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0169409X26001274"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":268,"alternative-id":["S0169409X26001274"],"URL":"https:\/\/doi.org\/10.1016\/j.addr.2026.115893","relation":{},"ISSN":["0169-409X"],"issn-type":[{"value":"0169-409X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"High-dose biologics and bioconjugates delivery: Integrating molecular optimization with device design and routes of administration","name":"articletitle","label":"Article Title"},{"value":"Advanced Drug Delivery Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.addr.2026.115893","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"115893"}}